Editas Medicine (EDIT) Stock: Buy, Sell, or Hold?
EDIT - Editas Medicine, Inc. Common Stock
$2.52
-0.05 (-1.95%)
▼
5d:
-8.36%
30d:
-17.92%
90d:
-30.96%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: EDIT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: EDIT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $2.52, which is considered oversold relative to its 30-day fair value range of $2.62 to $3.10.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.42, while resistance sits at $3.14.
Market Sentiment: EDIT scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.90 (+134.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.42, while resistance sits at $3.14.
Market Sentiment: EDIT scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.90 (+134.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.62 -
$3.10
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 134.1% below Wall St target ($5.90)
- CAUTION: Bottoming setup, but lagging the sector by 30% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-8.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$2.62 -
$3.10
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.42
Resistance Level
$3.14
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.35
Wall Street Target
$5.90
(+134.1%)
Revenue Growth (YoY)
232.3%
Profit Margin
-157.3%
Share & Embed Analysis
Last updated: October 02, 2026 1:16 AM ET
Data refreshes hourly during market hours. Next update: 2:16 AM
Data refreshes hourly during market hours. Next update: 2:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
